In the last trading session, 1.45 million Acadia Pharmaceuticals Inc (NASDAQ:ACAD) shares changed hands as the company’s beta touched 0.65. With the company’s per share price at $22.30 changed hands at $0.32 or 1.46% during last session, the market valuation stood at $3.73B. ACAD’s last price was a discount, traded about -13.14% off its 52-week high of $25.23. The share price had its 52-week low at $13.40, which suggests the last value was 39.91% up since then. When we look at Acadia Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.5 million shares, with the 3-month average coming to 2.06 million.
Analysts gave the Acadia Pharmaceuticals Inc (ACAD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.89. If we narrow down to specifics, the data shows that 1 out of 16 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ACAD as a Hold, 14 felt it is a Buy and 0 rated the stock as Underweight.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
Instantly ACAD was in green as seen at the end of in last trading. With action 3.89%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 21.53%, with the 5-day performance at 3.89% in the green. However, in the 30-day time frame, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) is 31.72% up. Looking at the short shares, we see there were 15.24 million shares sold at short interest cover period of 8.49 days.
The consensus price target for the stock as assigned by Wall Street analysts is 24, meaning bulls need an upside of 7.08% from its current market value. According to analyst projections, ACAD’s forecast low is 20 with 32 as the target high. To hit the forecast high, the stock’s price needs a -43.5% plunge from its current level, while the stock would need to tank 10.31% for it to hit the projected low.
The 2025 estimates are for Acadia Pharmaceuticals Inc earnings to decrease by -61.72%, but the outlook for the next 5-year period is at 4.70% per year.
ACAD Dividends
Acadia Pharmaceuticals Inc is expected to release its next quarterly earnings report on 2025-May-06.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.68% of Acadia Pharmaceuticals Inc shares while 105.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 106.30%. There are 105.58% institutions holding the Acadia Pharmaceuticals Inc stock share, with BAKER BROS. ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 25.9001% of the shares, roughly 42.88 million ACAD shares worth $696.77 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 8.2827% or 13.71 million shares worth $222.82 million as of 2024-06-30.
Among Mutual Funds, the top two as of Apr 30, 2025 were iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 7.48 shares estimated at $166.84 million under it, the former controlled 4.47% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.35% of the shares, roughly 3.94 shares worth around $87.88 million.
